Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125217351 | 12521735 | 1 | I | 20160603 | 20160624 | 20160701 | 20160701 | EXP | FR-ASTRAZENECA-2016SE70779 | ASTRAZENECA | 14407.00 | DY | M | Y | 0.00000 | 20160701 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125217351 | 12521735 | 1 | PS | INEXIUM | ESOMEPRAZOLE | 1 | Oral | 21153 | 1 | DF | QD | ||||||||
| 125217351 | 12521735 | 2 | SS | AMOXICILLINE SANDOZ | AMOXICILLIN | 1 | Intravenous (not otherwise specified) | N | U | 0 | 1 | G | TID | ||||||
| 125217351 | 12521735 | 3 | SS | SERESTA | OXAZEPAM | 1 | Oral | IF NEEDED | 0 | ||||||||||
| 125217351 | 12521735 | 4 | SS | BENERVA | THIAMINE | 1 | Intravenous (not otherwise specified) | U | U | 0 | 1 | G | QD | ||||||
| 125217351 | 12521735 | 5 | SS | LOVENOX | ENOXAPARIN SODIUM | 1 | Unknown | 0 | 4000 | IU | QD | ||||||||
| 125217351 | 12521735 | 6 | SS | PYRIDOXINE | PYRIDOXINE | 1 | Intravenous (not otherwise specified) | U | U | 0 | 500 | MG | QD | ||||||
| 125217351 | 12521735 | 7 | SS | PRINCI-B | CYANOCOBALAMINPYRIDOXINE HYDROCHLORIDETHIAMINE | 1 | Oral | 0 | 1 | DF | QD | ||||||||
| 125217351 | 12521735 | 8 | SS | ZAMUDOL | TRAMADOL HYDROCHLORIDE | 1 | Oral | U | U | 0 | 100 | MG | BID | ||||||
| 125217351 | 12521735 | 9 | SS | DOLIPRANE | ACETAMINOPHEN | 1 | Oral | 0 | 1 | DF | QD | ||||||||
| 125217351 | 12521735 | 10 | SS | AUGMENTIN | AMOXICILLINCLAVULANATE POTASSIUM | 1 | Oral | N | U | 0 | 1 | G | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125217351 | 12521735 | 1 | Gastrooesophageal reflux disease |
| 125217351 | 12521735 | 2 | Antibiotic prophylaxis |
| 125217351 | 12521735 | 3 | Alcoholism |
| 125217351 | 12521735 | 4 | Alcoholism |
| 125217351 | 12521735 | 5 | Prophylaxis |
| 125217351 | 12521735 | 6 | Alcoholism |
| 125217351 | 12521735 | 7 | Alcoholism |
| 125217351 | 12521735 | 8 | Pain |
| 125217351 | 12521735 | 9 | Pain |
| 125217351 | 12521735 | 10 | Antibiotic prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125217351 | 12521735 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125217351 | 12521735 | Erythema | |
| 125217351 | 12521735 | Lymphopenia | |
| 125217351 | 12521735 | Purpura | |
| 125217351 | 12521735 | Rash macular |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125217351 | 12521735 | 1 | 20160601 | 0 | ||
| 125217351 | 12521735 | 2 | 20160601 | 0 | ||
| 125217351 | 12521735 | 3 | 20160601 | 0 | ||
| 125217351 | 12521735 | 4 | 20160601 | 0 | ||
| 125217351 | 12521735 | 5 | 20160601 | 0 | ||
| 125217351 | 12521735 | 6 | 20160602 | 0 | ||
| 125217351 | 12521735 | 7 | 20160602 | 0 | ||
| 125217351 | 12521735 | 8 | 20160601 | 0 | ||
| 125217351 | 12521735 | 9 | 20160601 | 0 | ||
| 125217351 | 12521735 | 10 | 20160602 | 20160603 | 0 |